Insider · CIK 0001676170
Jason Coloma V
ceoofficerdirector
Files at MAZE (Maze Therapeutics, Inc.). First filing Sep 3, 2026, latest Oct 2, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $2.4M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MAZE: Maze Therapeutics, Inc.
MAZEOct 9, 2026 · close 27.11
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 64Notable | Maze Therapeutics, Inc. | $932k 34,501 shares | -190% | +19% from low-49% from high | |
| 69Notable | Maze Therapeutics, Inc. | $594k 22,638 shares | -45% | - | |
| 49Moderate | Maze Therapeutics, Inc. | $907k 34,501 shares | -166% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | MAZE Maze Therapeutics, Inc. | SOpen-market sale Common Stockindirect: The Coloma 2021 Irrevocable Trust10b5-1 | -2,593 | $27.02 | $70k | 15,558 | 10 d ago |
| Oct 1, 2026 | MAZE Maze Therapeutics, Inc. | SOpen-market sale Common Stockindirect: Coloma Family Trust10b5-1 | -31,908 | $27.02 | $862k | 191,447 | 10 d ago |
| Sep 2, 2026 | MAZE Maze Therapeutics, Inc. | SOpen-market sale Common Stock | -9,852 | $26.38 | $260k | 40,148 | 38 d ago |
| Sep 2, 2026 | MAZE Maze Therapeutics, Inc. | SOpen-market sale Common Stock | -1,375 | $27.12 | $37k | 38,773 | 38 d ago |
| Sep 3, 2026 | MAZE Maze Therapeutics, Inc. | SOpen-market sale Common Stock | -11,282 | $26.01 | $293k | 27,491 | 38 d ago |
| Sep 3, 2026 | MAZE Maze Therapeutics, Inc. | SOpen-market sale Common Stock | -129 | $25.77 | $3,325 | 27,362 | 38 d ago |
| Sep 1, 2026 | MAZE Maze Therapeutics, Inc. | SOpen-market sale Common Stockindirect: The Coloma 2021 Irrevocable Trust10b5-1 | -2,593 | $26.31 | $68k | 18,151 | 39 d ago |
| Sep 1, 2026 | MAZE Maze Therapeutics, Inc. | SOpen-market sale Common Stockindirect: Coloma Family Trust10b5-1 | -31,908 | $26.29 | $839k | 223,355 | 39 d ago |
| Sep 1, 2026 | MAZE Maze Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +50,000 | $0.00 | $0 | 50,000 | 39 d ago |
| Sep 1, 2026 | MAZE Maze Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -50,000 | $0.00 | $0 | 50,000 | 39 d ago |
| Sep 22, 2025 | MAZE Maze Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +100,000 | $0.00 | $0 | 100,000 | Sep 24, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.